OR WAIT null SECS
February 17, 2022
ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.
The deal between ProBioGen and AstraZeneca will allow AstraZeneca to use ProBioGen’s GlymaxX technology.
February 11, 2022
China-based CDMO Asymchem acquires US-based chemical technology company Snapdragon.
February 10, 2022
In an agreement with MaaT Pharma, Skyepharma will build MaaT a dedicated 1500-m² microbiome ecosystem therapies manufacturing site.
Sartorius Stedim Biotech has completed the acquisition of the chromatography equipment division of Novasep.
CGT Catapult has partnered with MICA Biosystems to advance MICA’s regenerative medicine technology to the UK’s MHRA.
February 08, 2022
MacroGenics will use Synaffix’s technology to investigate next-generation ADCs.
February 07, 2022
Gandeeva raisded $40 million to advance its AI-driven cryo-EM platform, with which it will develop new therapeutics based on the precise imaging of protein–drug interactions.
February 04, 2022
Domainex is collaborating with Parkinson’s UK for the development of small-molecule therapies targeting the neuroinflammation that is associated with Parkinson’s disease.
Zetta Genomics has raised £2.5 million ($3.4 million) in new seed funding.